Metabolic syndrome in Zambian adults with human immunodeficiency virus on antiretroviral therapy: Prevalence and associated factors.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
09 Apr 2021
09 Apr 2021
Historique:
received:
30
09
2020
accepted:
25
02
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
20
4
2021
Statut:
ppublish
Résumé
Metabolic syndrome (MetS) is a constellation of factors including hypertension, abdominal obesity, dyslipidemia, and insulin resistance that separately and together significantly increase risk for cardiovascular disease (CVD) and diabetes. In sub-Saharan Africa, with a substantial burden of human immunodeficiency virus (HIV) and increasing prevalence of CVD and diabetes, there is a paucity of epidemiological data on demographic, laboratory, and clinical characteristics associated with MetS among people with HIV (people with human [PWH]). Therefore, this study aimed to determine the burden and factors influencing MetS in antiretroviral therapy (ART)-experienced individuals in Zambia.We collected cross-sectional demographic, lifestyle, anthropometric, clinical, and laboratory data in a cohort of ART-experienced (on ART for ≥6 months) adults in 24 urban HIV treatment clinics of Zambia between August, 2016 and May, 2020. MetS was defined as having ≥3 of the following characteristics: low high density lipoprotein cholesterol (HDL-c) (<1.0 mmol/L for men, <1.3 for women), elevated waist circumference (≥94 cm for men, ≥80 cm for women), elevated triglycerides (≥1.7 mmol/L), elevated fasting blood glucose (≥5.6 mmol/L), and elevated blood pressure (BP) (systolic BP ≥130 or diastolic BP ≥85 mm Hg). Virological failure (VF) was defined as HIV viral load ≥1000 copies/mL. The following statistical methods were used: Chi-square test, Wilcoxon rank-sum test, and multivariable logistic regression.Among 1108 participants, the median age (interquartile range [IQR]) was 41 years (34, 49); 666 (60.1%) were females. The prevalence of MetS was 26.3% (95% confidence interval [CI] 23.9-29.1). Age (adjusted odds ratio [OR] 1.07; 95% CI 1.04-1.11), female sex (OR 3.02; 95% CI 1.55-5.91), VF (OR 1.98; 95% CI 1.01-3.87), dolutegravir (DTG)-based regimen (OR 2.10; 95% CI 1.05-4.20), hip-circumference (OR 1.03; 95% CI 1.01-1.05), T-lymphocyte count (OR 2.23; 95% CI 1.44-3.43), high-sensitivity C-reactive protein (hsCRP) (OR 1.14; 95% CI 1.01-1.29), and fasting insulin (OR 1.02; 95% CI 1.01-1.04) were significantly associated with MetS.Metabolic syndrome was highly prevalent among HIV+ adults receiving ART in Zambia and associated with demographic, clinical, anthropometric, and inflammatory characteristics. The association between MetS and dolutegravir requires further investigation, as does elucidation of the impact of MetS on ART outcomes in sub-Saharan African PWH.
Identifiants
pubmed: 33832083
doi: 10.1097/MD.0000000000025236
pii: 00005792-202104090-00027
pmc: PMC8036111
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25236Subventions
Organisme : FIC NIH HHS
ID : D43 TW009744
Pays : United States
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med J Br Diabet Assoc 1998;15:539–53.
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018;20:12.
Mazloomzadeh S, Karami Zarandi F, Shoghli A, et al. Metabolic syndrome, its components and mortality: a population-based study. Med J Islam Re∗pub Iran 2019;33:11.
Alvarez C, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 2010;14:256–63.
Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008;10:61–70.
Lombo B, et al. Prevalence of metabolic syndrome in patients with HIV in the era of highly active antiretroviral therapy. Conn Med 2015;79:277–81.
Guira O, et al. Features of metabolic syndrome and its associated factors during highly active antiretroviral therapy in Ouagadougou (Burkina Faso). J Int Assoc Provid AIDS Care 2016;15:159–63.
Li Vecchi V, Maggi P, Rizzo M, et al. The metabolic syndrome and HIV infection. Curr Pharm Des 2014;20:4975–5003.
Biron A, et al. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. AIDS Res Hum Retroviruses 2012;28:1672–8.
Bonfanti P, et al. The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study. Biomed Pharmacother 2012;66:348–53.
Jacobson DL, et al. Incidence of metabolic syndrome in a Cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). JAIDS J Acquir Immune Defic Syndr 2006;43:458.
Gazzaruso C, Sacchi P, Garzaniti A, et al. Prevalence of metabolic syndrome among hiv patients. Diabetes Care 2002;25:1253–4.
Palacios R, Santos J, González M, et al. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS 2007;18:184–7.
Sobieszczyk ME, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women's interagency HIV study. JAIDS J Acquir Immune Defic Syndr 2008;48:272.
Nguyen KA, Peer N, Mills EJ, et al. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PLoS One 2016;11:e0150970.
Keates AK, Mocumbi AO, Ntsekhe M, et al. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol 2017;14:273–93.
Alberti KGMM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.
Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:e285–350.
LeMessurier J, et al. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ 2018;190:E1350–60.
WHO. “Body mass index - BMI,”; 2020. Available at: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi (accessed Jan. 17, 2020).
Bune GT, Yalew AW, Kumie A. The global magnitude of metabolic syndrome among antiretroviral therapy (ART) exposed and ART-naïve adult HIV-infected patients in gedio-zone, southern Ethiopia: Comparative cross-sectional study, using the Adult Treatment Panel III criteria. Diabetes Metab Syndr 2019;13:2833–41.
Mbunkah HA, Meriki HD, Kukwah AT, et al. Prevalence of metabolic syndrome in human immunodeficiency virus - infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria. Diabetol Metab Syndr 2014;6:92.
Idiculla J, Ravindra’n GD, D'Souza J, et al. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India. Int J Gen Med 2011;4:73–8.
Theengh DP, Yadav P, Jain AK, et al. Assessment of metabolic syndrome in HIV-infected individuals. Indian J Sex Transm Dis AIDS 2017;38:152–6.
Jantarapakde J, et al. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDs 2014;28:331–40.
Policarpo S, Rodrigues T, Moreira AC, et al. Cardiovascular risk in HIV-infected individuals: a comparison of three risk prediction algorithms. Rev Port Cardiol 2019;38:463–70.
Worm SW, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010;24:427.
Osoti A, et al. Metabolic syndrome among antiretroviral therapy-naive versus experienced hiv-infected patients without preexisting cardiometabolic disorders in Western Kenya. AIDS Patient Care STDs 2018;32:215–22.
Labhardt ND, et al. Metabolic syndrome in patients on first-line antiretroviral therapy containing zidovudine or tenofovir in rural Lesotho, Southern Africa. Trop Med Int Health 2017;22:725–33.
Tesfaye DY, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr 2014;8:102–7.
Todowede OO, Mianda SZ, Sartorius B. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis. Syst Rev 2019;8:04.
Pangmekeh PJ, Awolu MM, Gustave S, et al. Association between highly active antiretroviral therapy (HAART) and hypertension in persons living with HIV/AIDS at the Bamenda regional hospital, Cameroon. Pan Afr Med J 2019;33:87.
Martin-Iguacel R, Negredo E, Peck R, et al. Hypertension is a key feature of the metabolic syndrome in subjects aging with HIV. Curr Hypertens Rep 2016;18:46.
Lagathu C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf 2019;18:829–40.
Rogalska-Płońska M, Grzeszczuk A, Rogalski P, et al. Metabolic syndrome in HIV infected adults in Poland. Kardiol Pol 2018;76:548–53.
Sears S, et al. Metabolic syndrome among people living with HIV receiving medical care in southern United States: prevalence and risk factors. AIDS Behav 2019;23:2916–25.
Su B-Y, Tian C-F, Gao B-L, et al. Correlation of the leucocyte count with traditional and non-traditional components of metabolic syndrome. Postgrad Med 2016;128:805–9.
Alencastro PR, Fuchs SC, Wolff FH, et al. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDs 2011;25:627–34.
Sax PE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis 2020;71:1379–89.
Bourgi K, et al. Greater weight gain in treatment-naive persons starting Dolutegravir-based antiretroviral therapy. Clin Infect Dis 2020;70:1267–74.
Katlama C, et al. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. J Antimicrob Chemother 2019;74:2742–51.
Fong PS, Flynn DM, Evans CD, et al. Integrase strand transfer inhibitor-associated diabetes mellitus: a case report. Int J STD AIDS 2017;28:626–8.
Lamorde M, et al. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV 2020;7:e461–2.
Katoto PDMC, et al. Prevalence and risk factors of metabolic syndrome in HIV-infected adults at three urban clinics in a post-conflict setting, eastern Democratic Rep∗ublic of the Congo. Trop Med Int Health 2018;23:795–805.
Wohl DA, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006;43:645–53.
Krishnan S, et al. “Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naïve HIV-infected individuals”. J Acquir Immune Defic Syndr 1999 2012;61:381–9.
Squillace N, et al. Detectable HIV viral load is associated with metabolic syndrome. J Acquir Immune Defic Syndr 1999 2009;52:459–64.
Dubé MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab 2011;25:429–42.
Hanley TM, Blay Puryear W, Gummuluru S, et al. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog 2010;6:e1000981.
Hanley TM, Viglianti GA. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J Virol 2011;85:10834–50.
da Cunha J, Maselli LMF, Stern ACB, et al. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs. World J Virol 2015;4:56–77.
Raposo MA, et al. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev Soc Bras Med Trop 2017;50:598–606.
Chen H, et al. Lymphocyte to high-density lipoprotein ratio as a new indicator of inflammation and metabolic syndrome. Diabetes Metab Syndr Obes Targets Ther 2019;12:2117–23.
Rodríguez CP, González MC, Aguilar-Salinas CA, et al. Peripheral lymphocytes, obesity, and metabolic syndrome in young adults: an immunometabolism study. Metab Syndr Relat Disord 2018;16:342–9.
Moro-García MA, Mayo JC, Sainz RM, et al. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes. Front Immunol 2018;9:339.
Pasini E, et al. Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. Cardiovasc Diabetol 2010;9:46.
Bersch N, Groopman JE, Golde DW. Natural and biosynthetic insulin stimulates the growth of human erythroid progenitors in vitro. J Clin Endocrinol Metab 1982;55:1209–11.
Katz EG, Stevens J, Truesdale KP, et al. Hip circumference and incident metabolic risk factors in chinese men and women: The People's Rep∗ublic of China Study. Metab Syndr Relat Disord 2011;9:55–62.
Rocha PM, Barata JT, Teixeira PJ, et al. Independent and opposite associations of hip and waist circumference with metabolic syndrome components and with inflammatory and atherothrombotic risk factors in overweight and obese women. Metabolism 2008;57:1315–22.
Snijder MB, Zimmet PZ, Visser M, et al. Independent association of hip circumference with metabolic profile in different ethnic groups. Obes Res 2004;12:1370–4.
Cho S-A, et al. Visceral fat area and serum adiponectin level predict the development of metabolic syndrome in a community-based asymptomatic population. PloS One 2017;12:e0169289.
Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629–39.
Nomura K, et al. Visceral fat accumulation and metabolic risk factor clustering in older adults. J Am Geriatr Soc 2010;58:1658–63.
Lake JE. The fat of the matter: obesity and visceral adiposity in treated HIV infection. Curr HIV/AIDS Rep 2017;14:211–9.
Yang YJ, et al. Relationship between the optimal cut-off values of anthropometric indices for predicting metabolic syndrome and carotid intima-medial thickness in a Korean population. Medicine (Baltimore) 2019;98:e17620.
Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest 2019;129:3990–4000.
Gadekar T, Dudeja P, Basu I, et al. Correlation of visceral body fat with waist-hip ratio, waist circumference and body mass index in healthy adults: a cross sectional study. Med J Armed Forces India 2020;76:41–6.
Bhagwat P, et al. Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther 2017;22:577–86.
Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007;30:113–9.
Swami A. Metabolic syndrome and HIV infection. J HIV Retro Virus 2016;2:
Barbaro G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr Pharm Des 2007;13:2208–13.
Qiao Q, Gao W, Zhang L, et al. Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 2007;44(pt 3):232–63.